New drug cocktail tested for aggressive blood cancers
NCT ID NCT03969446
Summary
This early-stage trial is testing a combination of three drugs (pembrolizumab, decitabine, and venetoclax) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has returned or not responded to prior treatment. The main goals are to find the safest dose and understand the side effects of this new combination. The study will also look for early signs that the treatment can put the cancer into remission.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.